Last reviewed · How we verify
Lamotrigine use
At a glance
| Generic name | Lamotrigine use |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neurophysiological Effects of Medication Tapering During Treatment With Spinal Cord Stimulation
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Enhancing the Effects of Alcohol Treatment With Lamotrigine (PHASE2)
- Neuromodulation for Central Post-stroke Pain: Mechanism, Safety and Outcome (NA)
- Antiepileptic Drugs in Elderly Patients
- Multicentre Study on Rapid Versus Slow Withdrawal of Antiepileptic Monotherapy (NA)
- Pharmacokinetics of Paracetamol and Antiepileptic Drugs After Sleeve Gastrectomy (PHASE4)
- Lamotrigine in Reducing Psychologic Side-Effect of Perioperative Ketamine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lamotrigine use CI brief — competitive landscape report
- Lamotrigine use updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI